Therapeutic Potential of Amanitin-Conjugated Anti-Epithelial Cell Adhesion Molecule Monoclonal Antibody Against Pancreatic Carcinoma | Zendy

Gerhard Moldenhauer | Zendy; Alexei V. Salnikov | Zendy; Sandra Lüttgau | Zendy; Ingrid Herr | Zendy; Jan Anderl | Zendy; Heinz Faulstich | Zendy

Open Access

Therapeutic Potential of Amanitin-Conjugated Anti-Epithelial Cell Adhesion Molecule Monoclonal Antibody Against Pancreatic Carcinoma

Author(s) -

Gerhard Moldenhauer,

Alexei V. Salnikov,

Sandra Lüttgau,

Ingrid Herr,

Jan Anderl,

Heinz Faulstich

Publication year - 2012

Publication title -

jnci journal of the national cancer institute

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.797

H-Index - 356

eISSN - 1460-2105

pISSN - 0027-8874

DOI - 10.1093/jnci/djs140

Subject(s) - epithelial cell adhesion molecule , monoclonal antibody , antibody drug conjugate , cancer research , antibody , pancreatic cancer , in vivo , chemistry , cell growth , apoptosis , microbiology and biotechnology , biology , immunology , cancer , medicine , biochemistry

Human epithelial cell adhesion molecule (EpCAM) is overexpressed in many cancers. Anti-EpCAM antibodies have shown promise in preclinical studies, but showed no tumor regression in a recent phase II clinical trial. Therefore, we generated a novel anti-EpCAM antibody-drug conjugate and assessed whether it showed enhanced antitumor effects.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research